Advertisement

Engineered Viruses as Vaccine Platforms

  • Antonella FolgoriEmail author
  • Stefania Capone
Chapter

Abstract

Many viruses have been investigated for the development of genetic vaccines and the ideal ones must be endowed with many properties, such as the quality and the quantity of the immunological response induced against the encoded antigens, safety and production on a large scale basis. Viral based vaccines must also deal with the potential problem of the pre-existing antivector immunity. Several viral vaccine vectors have emerged to date, all of them having relative advantages and limits depending on the proposed application. Recent successes reflect diverse improvements such as development of new adenovirus serotypes and prime-boost regimes. This chapter describes the features of four viral vector systems based on poxviruses, adenoviruses, alphaviruses and lentiviruses and recent results following their use with a particular emphasis on clinical research, highlighting the challenges and successes.

Keywords

Genetic vaccines Viral-vectored vaccines Adenovirus Poxvirus Alphavirus Lentivirus Heterologous prime-boost 

References

  1. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, Hanlon M, Spencer AJ, Honeycutt JD, Wyllie DH, Gilbert SC, Bregu M, Hill AV (2010) Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2:19ra12PubMedGoogle Scholar
  2. Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia strain: comparison with other orthopoxviruses. Virology 244:365–396PubMedGoogle Scholar
  3. Appaiahgari MB, Vrati S (2010) IMOJEV((R)): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vac 9:1371–1384Google Scholar
  4. Appledorn DM, Aldhamen YA, Depas W, Seregin SS, Liu CJ, Schuldt N, Quach D, Quiroga D, Godbehere S, Zlatkin I, Kim S, McCormick JJ, Amalfitano A (2010) A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One 5:e9579PubMedGoogle Scholar
  5. Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R (2011) Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis 204:1541–1549PubMedGoogle Scholar
  6. Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849–862PubMedGoogle Scholar
  7. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E (2008) Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108–6118PubMedGoogle Scholar
  8. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus A, Ammendola V, Naddeo V, O’Hara V, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill AS, Colloca S, Nicosia A, Cortese R, Klenerman P (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111Google Scholar
  9. Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5:386–390PubMedGoogle Scholar
  10. Beignon AS, Mollier K, Liard C, Coutant F, Munier S, Riviere J, Souque P, Charneau P (2009) Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 83:10963–10974PubMedGoogle Scholar
  11. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493PubMedGoogle Scholar
  12. Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR (2010) Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 28:7881–7889PubMedGoogle Scholar
  13. Bokhoven M, Stephen SL, Knight S, Gevers EF, Robinson IC, Takeuchi Y, Collins MK (2009) Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol 83:283–294PubMedGoogle Scholar
  14. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893PubMedGoogle Scholar
  15. Buffa V, Negri DR, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A (2006) A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol 87:1625–1634PubMedGoogle Scholar
  16. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, Nicosia A, Colloca S, Cortese R, Folgori A, Hill AV (2010) Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29:256–265PubMedGoogle Scholar
  17. Carey JB, Pearson FE, Vrdoljak A, McGrath MG, Crean AM, Walsh PT, Doody T, O’Mahony C, Hill AV, Moore AC (2011) Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One 6:e22442PubMedGoogle Scholar
  18. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77:6305–6313PubMedGoogle Scholar
  19. Casimiro DR, Bett AJ, Fu TM, Davies ME, Tang A, Wilson KA, Chen M, Long R, McKelvey T, Chastain M, Gurunathan S, Tartaglia J, Emini EA, Shiver J (2004) Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78:11434–11438PubMedGoogle Scholar
  20. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194:1638–1649PubMedGoogle Scholar
  21. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M, Wu TC (2002) Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13:553–568PubMedGoogle Scholar
  22. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, Lally M, Dolin R, Blattner W, Kalichman A, Figueroa JP, Pape J, Schechter M, Defawe O, De Rosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC (2011) A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 6:e21225PubMedGoogle Scholar
  23. Collins MK, Cerundolo V (2004) Gene therapy meets vaccine development. Trends Biotechnol 22:623–626PubMedGoogle Scholar
  24. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani A, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O’Hara GA, Ewer KJ, Anagnostou Bliss, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A (2012) Vaccine vectors derived from a large collection of Simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4(115):ra112Google Scholar
  25. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15:421–431PubMedGoogle Scholar
  26. Coutant F, Frenkiel MP, Despres P, Charneau P (2008) Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One 3:e3973PubMedGoogle Scholar
  27. Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE (2002) Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53:209–211PubMedGoogle Scholar
  28. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8:62–73PubMedGoogle Scholar
  29. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F, Hill AV (2008) Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14:819–821PubMedGoogle Scholar
  30. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, Naddeo M, Dicks MD, Faber BW, de Cassan SC, Folgori A, Nicosia A, Gilbert SC, Hill AV (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185:7583–7595PubMedGoogle Scholar
  31. Duerr A, Wasserheit JN, Corey L (2006) HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43:500–511PubMedGoogle Scholar
  32. Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC (2007) A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 13:3999–4008PubMedGoogle Scholar
  33. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR (2003) In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 111:1673–1681PubMedGoogle Scholar
  34. Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM (2001) Replication-defective vector based on a chimpanzee adenovirus. J Virol 75:11603–11613PubMedGoogle Scholar
  35. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC (2003) A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170:1416–1422PubMedGoogle Scholar
  36. Foged C, Hansen J, Agger EM (2011) License to kill: formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci. doi: 10.1016/j.ejps.2011.08.016
  37. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J (2004) Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vac 3(4 Suppl):S75–S88Google Scholar
  38. Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ (2011) Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 85:4222–4233PubMedGoogle Scholar
  39. Greer CE, Zhou F, Legg HS, Tang Z, Perri S, Sloan BA, Megede JZ, Uematsu Y, Vajdy M, Polo JM (2007) A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25:481–489PubMedGoogle Scholar
  40. Gupta S, Zhou F, Greer CE, Legg H, Tang T, Luciw P, zurMegede J, Barnett SW, Donnelly JJ, O’Hagan DT, Polo JM, Vajdy M (2006) Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses 22:993–997PubMedGoogle Scholar
  41. Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E (2009) Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vac Immunol 16:1285–1292Google Scholar
  42. Hawkridge T, Scriba TJ, Gelderbloem S, Smit E, Tameris M, Moyo S, Lang T, Veldsman A, Hatherill M, Merwe L, Fletcher HA, Mahomed H, Hill AV, Hanekom WA, Hussey GD, McShane H (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198:544–552PubMedGoogle Scholar
  43. He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr (2005) Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 174:3808–3817PubMedGoogle Scholar
  44. Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vac 6:78–83Google Scholar
  45. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD (1996) Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70:3741–3752PubMedGoogle Scholar
  46. Holst PJ, Sorensen MR, Mandrup Jensen CM, Orskov C, Thomsen AR, Christensen JP (2008) MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J Immunol 180:3339–3346PubMedGoogle Scholar
  47. Holst PJ, Bassi MR, Thomsen AR, Christensen JP (2010) DNA fusion gene vaccines. Curr Opin Mol Ther 12:47–54PubMedGoogle Scholar
  48. Holst PJ, Christensen JP, Thomsen AR (2011) Vaccination against lymphocytic choriomeningitis virus infection in MHC class II-deficient mice. J Immunol 18:3997–4007Google Scholar
  49. Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC (2004) Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22:3993–4001PubMedGoogle Scholar
  50. Hu B, Yang H, Dai B, Tai A, Wang P (2009) Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 20:1652–1664PubMedGoogle Scholar
  51. Hu B, Dai B, Wang P (2010) Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28:6675–6683PubMedGoogle Scholar
  52. Hu B, Tai A, Wang P (2011) Immunization delivered by lentiviral vectors for cancer and infectious diseases. Immunol Rev 239:45–61PubMedGoogle Scholar
  53. Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, Kierstead L, Ratcliffe SJ, Robertson MN, Casimiro DR, Ertl HC, Betts MR (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 15:876–878PubMedGoogle Scholar
  54. IAVI Report: IAVI database of AIDS vaccines in human trials. http://www.iavireport.org/trialsdb. Accessed 30 Dec 2011
  55. Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, Charneau P (2007) Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 15:1203–1210PubMedGoogle Scholar
  56. Kahl CA, Bonnell J, Hiriyanna S, Fultz M, Nyberg-Hoffman C, Chen P, King CR, Gall JG (2010) Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28:5691–5702PubMedGoogle Scholar
  57. Karwacz K, Mukherjee S, Apolonia L, Blundell MP, Bouma G, Escors D, Collins MK, Thrasher AJ (2009) Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83:3094–3103PubMedGoogle Scholar
  58. Kim PS, Ahmed R (2010) Features of responding T cells in cancer and chronic infection. Curr Opin Immunol 22:223–230PubMedGoogle Scholar
  59. Lasaro MO, Ertl HC (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17:1333–1339PubMedGoogle Scholar
  60. Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, Rux JJ, Wherry EJ, Cohen GH, Eisenberg RJ, Ertl HC (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat Med 14:205–212PubMedGoogle Scholar
  61. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, Koup RA, Roederer M, Bailer R, Mascola JR, Pau MG, Sullivan NJ, Goudsmit J, Nabel GJ, Graham BS (2010) A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:304–313PubMedGoogle Scholar
  62. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79:9694–9701PubMedGoogle Scholar
  63. Liu MA (2010) Gene-based vaccines: recent developments. Curr Opin Mol Ther 12:86–93PubMedGoogle Scholar
  64. Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87–91PubMedGoogle Scholar
  65. Lopes L, Dewannieux M, Takeuchi Y, Collins MK (2011) A lentiviral vector pseudotype suitable for vaccine development. J Gene Med 13:181–187PubMedGoogle Scholar
  66. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894–1905PubMedGoogle Scholar
  67. Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, Templeton NS, Schluns K, Buchl SS, Sastry KJ, Barry MA (2007) Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25:8687–8701PubMedGoogle Scholar
  68. Meyer H, Sutter G, Mayr A (1991) Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72:1031–1038PubMedGoogle Scholar
  69. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C, Naldini L (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687–696PubMedGoogle Scholar
  70. Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV (2004a) Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 189:2213–2219PubMedGoogle Scholar
  71. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, Pinder M, Gilbert SC, Walraven G, Greenwood BM, Hill AS (2004b) A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1:e33PubMedGoogle Scholar
  72. Nardin E (2010) The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin 6:27–38PubMedGoogle Scholar
  73. Naslund TI, Kostic L, Nordstrom EK, Chen M, Liljestrom P (2011) Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines. Virol J 8:36PubMedGoogle Scholar
  74. Negri DR, Michelini Z, Baroncelli S, Spada M, Vendetti S, Buffa V, Bona R, Leone P, Klotman ME, Cara A (2007) Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15:1716–1723PubMedGoogle Scholar
  75. Negri DR, Michelini Z, Bona R, Blasi M, Filati P, Leone P, Rossi A, Franco M, Cara A (2011) Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opin Biol Ther 11:739–750PubMedGoogle Scholar
  76. O’Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH (2009) Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 15:873–875PubMedGoogle Scholar
  77. O’Hara GA, Duncan CJA, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AVS (2012) Clinical assessment of a recombinant Simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205(5):772–81. Epub 2012 Jan 24Google Scholar
  78. Parrino J, Graham BS (2006) Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol 118:1320–1326PubMedGoogle Scholar
  79. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25:1513–1525PubMedGoogle Scholar
  80. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080PubMedGoogle Scholar
  81. Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW Jr, Vajdy M, Otten GR, Polo JM (2003) An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77:10394–10403PubMedGoogle Scholar
  82. Philippe S, Sarkis C, Barkats M, Mammeri H, Ladroue C, Petit C, Mallet J, Serguera C (2006) Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 103:17684–17689PubMedGoogle Scholar
  83. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46:1769–1781PubMedGoogle Scholar
  84. Radosevic K, Rodriguez A, Lemckert AA, van der Meer M, Gillissen G, Warnar C, von Eyben R, Pau MG, Goudsmit J (2010) The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol 17(11):1687–1694PubMedGoogle Scholar
  85. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220PubMedGoogle Scholar
  86. Reyes-Sandoval A, Ertl HC (2001) DNA vaccines. Curr Mol Med 1:217–243PubMedGoogle Scholar
  87. Reyes-Sandoval A, Fitzgerald JC, Grant R, Roy S, Xiang ZQ, Li Y, Gao GP, Wilson JM, Ertl HC (2004) Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J Virol 78:7392–7399PubMedGoogle Scholar
  88. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38:732–741PubMedGoogle Scholar
  89. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, Colloca S, Cortese R, Hill AV (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78:145–153PubMedGoogle Scholar
  90. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239–243PubMedGoogle Scholar
  91. Roy S, Medina-Jaszek A, Wilson MJ, Sandhu A, Calcedo R, Lin J, Wilson JM (2011) Creation of a panel of vectors based on ape adenovirus isolates. J Gene Med 13:17–25PubMedGoogle Scholar
  92. Schirmbeck R, Reimann J, Kochanek S, Kreppel F (2008) The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 16:1609–1616PubMedGoogle Scholar
  93. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks M, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ (2011) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19:2269–2276PubMedGoogle Scholar
  94. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335PubMedGoogle Scholar
  95. Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005a) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113:259–266PubMedGoogle Scholar
  96. Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, Dunbar PR, Sette A, Harris AL, Cerundolo V (2005b) Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 175:8431–8437PubMedGoogle Scholar
  97. Soloff AC, Liu X, Gao W, Day RD, Gambotto A, Barratt-Boyes SM (2009) Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection. Eur J Immunol 39:2437–2449PubMedGoogle Scholar
  98. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus AD (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700–3709PubMedGoogle Scholar
  99. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3:e177PubMedGoogle Scholar
  100. Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629PubMedGoogle Scholar
  101. Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson JM, Ertl HC (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13:421–429PubMedGoogle Scholar
  102. Thornburg NJ, Ray CA, Collier ML, Liao HX, Pickup DJ, Johnston RE (2007) Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology 362:441–452PubMedGoogle Scholar
  103. Tutykhina IL, Logunov DY, Shcherbinin DN, Shmarov MM, Tukhvatulin AI, Naroditsky BS, Gintsburg AL (2011) Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med 89:331–341PubMedGoogle Scholar
  104. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa HY, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD (2010) Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B’/C candidate vaccine. PLoS One 5:e8816PubMedGoogle Scholar
  105. Wang HB, Kondo A, Yoshida A, Yoshizaki S, Abe S, Bao LL, Mizuki N, Ichino M, Klinman D, Okuda K, Shimada M (2010) Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther 17:4–13PubMedGoogle Scholar
  106. Wanisch K, Yanez-Munoz RJ (2009) Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 17:1316–1332PubMedGoogle Scholar
  107. Wyatt LS, Earl PL, Eller LA, Moss B (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 101:4590–4595PubMedGoogle Scholar
  108. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC (2002) Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76:2667–2675PubMedGoogle Scholar
  109. Xu R, Srivastava IK, Greer CE, Zarkikh I, Kraft Z, Kuller L, Polo JM, Barnett SW, Stamatatos L (2006) Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 22:1022–1030PubMedGoogle Scholar
  110. Yang L, Yang H, Rideout K, Cho T, Joo KI, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, Wang P (2008) Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 26:326–334PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.OkairosPomezia, RomeItaly

Personalised recommendations